JP2020533302A - 肥満の治療において使用するためのｍｉｃ−１およびｇｌｐ−１ - Google Patents

肥満の治療において使用するためのｍｉｃ−１およびｇｌｐ−１ Download PDF

Info

Publication number
JP2020533302A
JP2020533302A JP2020513684A JP2020513684A JP2020533302A JP 2020533302 A JP2020533302 A JP 2020533302A JP 2020513684 A JP2020513684 A JP 2020513684A JP 2020513684 A JP2020513684 A JP 2020513684A JP 2020533302 A JP2020533302 A JP 2020533302A
Authority
JP
Japan
Prior art keywords
mic
compound
glp
hsa
administered
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2020513684A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020533302A5 (https=
Inventor
セバスチャン・ベック・イェルゲンセン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novo Nordisk AS
Original Assignee
Novo Nordisk AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Nordisk AS filed Critical Novo Nordisk AS
Publication of JP2020533302A publication Critical patent/JP2020533302A/ja
Publication of JP2020533302A5 publication Critical patent/JP2020533302A5/ja
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/643—Albumins, e.g. HSA, BSA, ovalbumin or a Keyhole Limpet Hemocyanin [KHL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Nutrition Science (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Physiology (AREA)
  • Dermatology (AREA)
  • Molecular Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
JP2020513684A 2017-09-10 2018-09-10 肥満の治療において使用するためのｍｉｃ−１およびｇｌｐ−１ Withdrawn JP2020533302A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP17190270.3 2017-09-10
EP17190270 2017-09-10
PCT/EP2018/074263 WO2019048660A1 (en) 2017-09-10 2018-09-10 MIC-1 AND GLP-1 FOR USE IN THE TREATMENT OF OBESITY

Publications (2)

Publication Number Publication Date
JP2020533302A true JP2020533302A (ja) 2020-11-19
JP2020533302A5 JP2020533302A5 (https=) 2021-09-24

Family

ID=59901361

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020513684A Withdrawn JP2020533302A (ja) 2017-09-10 2018-09-10 肥満の治療において使用するためのｍｉｃ−１およびｇｌｐ−１

Country Status (6)

Country Link
US (1) US11260108B2 (https=)
EP (1) EP3681529A1 (https=)
JP (1) JP2020533302A (https=)
CN (1) CN111163795A (https=)
MA (1) MA50233A (https=)
WO (1) WO2019048660A1 (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10588980B2 (en) 2014-06-23 2020-03-17 Novartis Ag Fatty acids and their use in conjugation to biomolecules
EP3934679A1 (en) * 2019-03-08 2022-01-12 Amgen Inc. Growth differentiation factor 15 combination therapy
US12544427B2 (en) 2019-10-04 2026-02-10 Amgen Inc. Use of GDF15 for treating cardiometabolic syndrome and other conditions
BR112022011540A2 (pt) * 2019-12-11 2022-09-06 Lg Chemical Ltd Polipeptídeo de fusão compreendendo gdf15, composição farmacêutica que compreende o mesmo, dímero e método de preparação do dito polipeptídeo, método para aumentar a estabilidade in vivo de gdf15, molécula de ácido nucleico, vetor e célula recombinantes e uso terapêutico do dito polipeptídeo e dímero
CN115260313B (zh) * 2019-12-31 2023-07-18 北京质肽生物医药科技有限公司 Glp-1和gdf15的融合蛋白以及其缀合物
CN111234015B (zh) * 2020-02-12 2021-04-06 康维众和(中山)生物药业有限公司 用于延长药物半衰期的抗体、其融合蛋白和应用
WO2022089435A1 (en) 2020-10-27 2022-05-05 Beijing Ql Biopharmaceutical Co., Ltd. Fusion proteins of gdf15 and use thereof
CA3219645A1 (en) * 2021-05-21 2022-11-24 Yuhan Corporation Composition for combination therapy comprising growth differentiation factor-15 variant and glucagon-like peptide-1 receptor agonist

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014505087A (ja) * 2011-02-09 2014-02-27 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 医薬組成物、治療するための方法およびその使用
JP2015518468A (ja) * 2012-03-27 2015-07-02 エヌジーエム バイオファーマシューティカルス，インコー 代謝障害を治療するための組成物および方法

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5424286A (en) 1993-05-24 1995-06-13 Eng; John Exendin-3 and exendin-4 polypeptides, and pharmaceutical compositions comprising same
IL128332A0 (en) 1996-08-30 2000-01-31 Novo Nordisk As GLP-1 derivatives
EP1734986B1 (en) 2004-04-13 2015-11-11 St Vincent's Hospital Sydney Limited Method for modulating appetite
TWI372629B (en) 2005-03-18 2012-09-21 Novo Nordisk As Acylated glp-1 compounds
CN103533951B (zh) * 2011-04-08 2017-04-19 安姆根有限公司 使用生长分化因子15(gdf‑15)治疗或改善代谢障碍的方法
JP2015506373A (ja) 2012-01-26 2015-03-02 アムジエン・インコーポレーテツド 成長分化因子１５（ｇｄｆ−１５）ポリペプチド
CA2899170C (en) 2013-01-30 2022-08-02 Ngm Biopharmaceuticals, Inc. Compositions and methods of use in treating metabolic disorders
TWI648401B (zh) 2013-07-31 2019-01-21 安美基公司 生長分化因子１５（ｇｄｆ－１５）構築體
EP3157947A1 (en) 2014-06-23 2017-04-26 Novartis AG Hsa-gdf-15 fusion polypeptide and use thereof
EP3160496B1 (en) 2014-06-24 2021-03-03 Novo Nordisk As Mic-1 fusion proteins and uses thereof
MX370115B (es) 2014-07-30 2019-12-02 Ngm Biopharmaceuticals Inc Dímeros que comprenden dos polipéptidos, útiles en el tratamiento de trastornos metabólicos.
PL3212226T3 (pl) 2014-10-31 2020-11-02 Ngm Biopharmaceuticals, Inc. Kompozycje i sposoby stosowania w leczeniu zaburzeń metabolicznych
CN108367053A (zh) 2015-12-22 2018-08-03 诺华股份有限公司 使用生长分化因子15(gdf-15)治疗或改善代谢性疾病的方法
WO2017121865A1 (en) 2016-01-15 2017-07-20 Novo Nordisk A/S Mic-1 receptor and uses thereof

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014505087A (ja) * 2011-02-09 2014-02-27 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 医薬組成物、治療するための方法およびその使用
JP2015518468A (ja) * 2012-03-27 2015-07-02 エヌジーエム バイオファーマシューティカルス，インコー 代謝障害を治療するための組成物および方法

Also Published As

Publication number Publication date
US20200197491A1 (en) 2020-06-25
WO2019048660A1 (en) 2019-03-14
EP3681529A1 (en) 2020-07-22
US11260108B2 (en) 2022-03-01
CN111163795A (zh) 2020-05-15
MA50233A (fr) 2020-07-22

Similar Documents

Publication Publication Date Title
US11260108B2 (en) MIC-1 and GLP-1 for use in the treatment of obesity
US10335462B2 (en) Use of long-acting GLP-1 peptides
JP6379300B2 (ja) ＧＬＰ及び免疫グロブリンハイブリッドＦｃ融合ポリペプチド及びその用途
JP6591562B2 (ja) 融合タンパク質
JP6385345B2 (ja) 持続型インスリン分泌性ペプチド結合体の液状製剤
US8557769B2 (en) Co-administration of FGF-21 and GLP-1 to treat diabetes and lower blood glucose
JP7475276B2 (ja) Ｆｇｆ２１バリアント、融合タンパク質及びそれらの適用
US20080213288A1 (en) Combined Use Of A Modulator Of CD3 And A GLP-1 Compound
BR112015001593B1 (pt) Formulação líquida de uma combinação de insulina e de peptídeo insulinotrópico de longa duração e método para a preparação da dita formulação líquida
JP2014159431A (ja) 血糖降下剤の投与方法
EP1515749B1 (en) Combined use of a modulator of cd3 and a glp-1 compound
KR20090059155A (ko) 장기 지속형 혈당 강하제의 투여 방법
EP3558344A1 (en) Glucagon-like peptide 1 (glp-1) receptor agonist compositions
EP4144362A1 (en) Compositions comprising short-acting hormones for treating or preventing obesity and pumps comprising said composition
JP2025166052A (ja) 肥満の治療における使用のためのｉｌ－４由来ペプチド
BR112017020502B1 (pt) Proteína de fusão e seus usos, homodímero e seus usos, e composição farmacêutica
BR112016027469B1 (pt) Composições farmacêuticas para a prevenção ou tratamento de diabetes mellitus

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210810

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20210810

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20220531

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220606

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20220822

A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20221206